We are fascinated by the ability of tumors to evade immune elimination. Most of our current programs focus on restoring the power of the immune system to achieve clean tumor kills. Tumors subvert immunity in a variety of ways. They can hide their very existence from innate cellular alarm systems and circulating surveillance immune cells, frustrate the buildup and amplification of immune responses and subvert established inflammatory responses by evoking potent immunosuppressive factors.
The recent approvals of inhibitors targeting checkpoint blockade are the first steps in the establishment of immuno-oncology as durable method of treating a number of cancers. The coming decade will see the emergence of new generations of immune system targeted oncology drugs which can be used as monotherapy or in combination with other immuno-oncology agents or existing drugs.
Curadev attracts passionate, creative people and builds extraordinarily productive teams. Through a careful recruiting process, Curadev has built a well-knit team of scientific investigators who thrive on the constant challenges of drug discovery research.
Curadev has a world-class scientific advisory board that works in close association with Curadev scientists to identify new research directions and accelerate Curadev’s target validation and drug discovery programs.
June 2 - 7, 2017
B 87, Sector 83, Noida, UP 201305, INDIA
Tel: +91-120-408 1818/19
Fax: +91-120-408 1820